Aiming for Best Outcomes: Optimizing Myelofibrosis Treatment and Management

01 May 2022
Aiming for Best Outcomes: Optimizing
Myelofibrosis Treatment and Management
At the recent Malaysia MPN Expert Forum, Dr Harry Gill, Clinical Assistant Professor at the University of Hong Kong, presented a review of the current treatment landscape in myelofibrosis (MF), along with a detailed look at the optimization of Jakavi® (ruxolitinib), Novartis in MF management. The forum was organized in collaboration between Novartis and the Malaysian Society of Haematology (MSH).

Related MIMS Drugs

Editor's Recommendations